Company intelligence / Profile preview

AdnaGen

Langenhagen/Hannover, Lower Saxony, Germanyzoominfo.com ↗

Ownership: Private
Development stage: Other

Overview

Developed and commercialized molecular diagnostic tests for the detection of circulating tumor cells in blood, primarily used in oncology research and clinical diagnostics. The company’s technology enabled sensitive detection of cancer biomarkers from patient samples. After acquisition by QIAGEN, the products/technology continued under QIAGEN’s portfolio. No current independent clinical pipeline as a standalone entity post-acquisition. Clinical results supported use in cancer monitoring and research settings prior to integration into QIAGEN.

Therapeutic areas: Oncology
Modalities: Diagnostic test (Molecular diagnostic technology)
Industry: Molecular Diagnostics

Partnerships

Integrated with QIAGEN after acquisition; no major external partnerships reported pre-acquisition.

Beyond the preview

Go deeper on AdnaGen.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AdnaGen.

Explore the full profile